Bone Marrow Suppression Due To Folic Acid Antagonism — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for bone marrow suppression due to folic acid antagonism. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2039. Daily refresh.

1
Approved drugs
2
Active US patents
50/100
Avg vulnerability
—
Annual revenue covered

Originators in Bone Marrow Suppression Due To Folic Acid Antagonism

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Acrotech Biopharma 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating bone marrow suppression due to folic acid antagonism. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Fusilev
levoleucovorin
 Acrotech Biopharma 2 50 — 2039-03-25

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11541012 Fusilev formulation 50 2039-03-25
11541012 Fusilev formulation 50 2039-03-25

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11541012 Fusilev formulation 50 2039-03-25
11541012 Fusilev formulation 50 2039-03-25

Related